Jim Mellon

Jim Mellon is a UK biotech investor, longevity investor (co-founder of Juvenescence), and serial entrepreneur based on the Isle of Man, writing $250k+ checks at pre-seed and seed in biotech and life sciences tools. His longevity-thesis profile is one of the most distinctive in the European biotech angel and family-office ecosystem, and his Burnbrae and Juvenescence vehicles give him real category leadership in aging biology, regenerative medicine, and longevity-adjacent biotech. Founders building longevity-focused biotech, regenerative medicine, life sciences tools enabling aging research, or therapeutics targeting age-related disease are the natural fit and should treat him as a top-of-list target. He is the wrong audience for digital health, devices, AI-only plays where the biology is thin, or anything outside the longevity and biotech orbit. The check size and signal value are significant, and a yes from Mellon often pulls other longevity-thesis capital. With no LinkedIn or Twitter listed, the realistic outreach path is through Juvenescence, Burnbrae, or the longevity research and investor community (Longevity Vision Fund, Foresight Institute, aging-biology academic networks). Cold outreach is low-yield. Diligence will be biology-fluent, so come with strong scientific founders, peer-reviewed data or credible preclinical work, and a clear longevity narrative rather than a generic biotech pitch.